X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Forecasted to Earn FY2023 Earnings of ($0.64) Per Share

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) – Analysts at Cantor Fitzgerald upped their FY2023 EPS estimates for X4 Pharmaceuticals in a research note issued on Monday, May 22nd. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($0.64) for the year, up from their prior forecast of ($0.76). Cantor Fitzgerald has a “Overweight” rating and a $3.00 price objective on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.63) per share.

X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) last released its quarterly earnings results on Tuesday, March 21st. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06).

XFOR has been the topic of a number of other research reports. B. Riley cut their price target on X4 Pharmaceuticals from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, April 10th. HC Wainwright lowered their price objective on shares of X4 Pharmaceuticals from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, March 22nd. Stifel Nicolaus raised their price objective on shares of X4 Pharmaceuticals from $4.00 to $5.00 in a research note on Wednesday, May 17th. Finally, Oppenheimer lowered their price objective on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set an “outperform” rating on the stock in a research note on Friday, March 24th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $3.50.

X4 Pharmaceuticals Stock Performance

XFOR opened at $2.01 on Wednesday. The business’s 50 day moving average is $1.32 and its 200-day moving average is $1.21. The stock has a market cap of $245.64 million, a PE ratio of -1.53 and a beta of 0.70. The company has a current ratio of 5.04, a quick ratio of 5.04 and a debt-to-equity ratio of 0.62. X4 Pharmaceuticals has a twelve month low of $0.65 and a twelve month high of $2.41.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. NEA Management Company LLC acquired a new position in X4 Pharmaceuticals in the 3rd quarter worth approximately $11,155,000. Perceptive Advisors LLC acquired a new stake in shares of X4 Pharmaceuticals during the 1st quarter valued at $3,955,000. Bain Capital Life Sciences Investors LLC boosted its stake in shares of X4 Pharmaceuticals by 111.6% during the 3rd quarter. Bain Capital Life Sciences Investors LLC now owns 6,389,436 shares of the company’s stock valued at $10,926,000 after buying an additional 3,369,896 shares during the period. AXA S.A. boosted its stake in shares of X4 Pharmaceuticals by 258.7% during the 3rd quarter. AXA S.A. now owns 4,126,460 shares of the company’s stock valued at $7,056,000 after buying an additional 2,975,993 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of X4 Pharmaceuticals by 348.6% during the 3rd quarter. Vanguard Group Inc. now owns 3,208,103 shares of the company’s stock valued at $5,486,000 after buying an additional 2,492,928 shares during the period. Institutional investors and hedge funds own 56.46% of the company’s stock.

About X4 Pharmaceuticals

(Get Rating)

X4 Pharmaceuticals, Inc operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003.